Kyverna Therapeutics, Inc.
KYTX
Rank in Stocks
#14485
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Share Price
$5.17
Last synced: 2026-11-09
Market Cap
$319.73M
Change (1 day)
5.94%
Change (1 year)
-20.22%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Kyverna Therapeutics, Inc. (KYTX)
Category
Healthcare
Operating Margin for Kyverna Therapeutics, Inc. (KYTX)
Operating Margin as of November 2026 TTM: 0.00%
According to Kyverna Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Kyverna Therapeutics, Inc. from 2021 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | -100.00% |
| 2022 | -418.28% | -10.20% |
| 2021 | -465.81% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Kyverna Therapeutics, Inc.'s operating margin
What was Kyverna Therapeutics, Inc.'s operating margin in 2025?
In 2025, Kyverna Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Kyverna Therapeutics, Inc.'s operating margin changed since 2021?
From 2021 to 2025, Kyverna Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2021 (-465.81%).
How does Kyverna Therapeutics, Inc.'s operating margin compare with similar companies?
Kyverna Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.